Citadel Advisors
ESLAW icon

Citadel Advisors’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Citadel Advisors’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,920
Closed -$2.01K – 14510
2023
Q2 		$2.01K Buy
+50,920
New +$3.48K ﹤0.01% 13844

Other funds holding ESLAW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

Citadel Advisors's ESLAW Position: Q3 2023 in Review

Citadel Advisors sold out of Estrella Immunopharma Warrant (ESLAW) in Q3 2023, closing a stake of 50,920 shares — an estimated $2.01K sold.

Citadel Advisors first reported a position in ESLAW in Q2 2023 and held it in 1 quarter. The position peaked at $2.01K in Q2 2023. 11 funds tracked by Wall St. Rank hold ESLAW as of Q3 2023.

  • Citadel Advisors reported no remaining Estrella Immunopharma Warrant position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 50,920 Estrella Immunopharma Warrant shares in Q3 2023, an estimated $2.01K.
  • Citadel Advisors first reported a position in Estrella Immunopharma Warrant in Q2 2023 and held it in 1 quarter.
  • Citadel Advisors's Estrella Immunopharma Warrant position peaked at $2.01K in Q2 2023.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.